Peter J. Neumann, ScD; Jennifer A. Palmer, MS; Norman Daniels, PhD; Karen Quigley, MPH; Marthe R. Gold, MD; and Schumarry Chao, MD, MBA, for the Panel on Integrating Cost-Effectiveness Considerations into Health Policy Decisions

A panel composed of medical and pharmacy directors expressed strong support for a greater role for cost-effectiveness analysis in US health policy decisions.

Scott V. Monte, PharmD; Nicole M. Paolini, PharmD; Erin M. Slazak, PharmD; Jerome J. Schentag, PharmD; and Joseph A. Paladino, PharmD

Compared with other costs of treatment, expenditures for antibiotics were nominal in an adult primary care population with lower respiratory tract infections.

Nadereh Pourat, PhD; Guoyu A. Tao, PhD; and Cathleen M.Walsh, DrPh

Among young, sexually active women, self-reported Chlamydia trachomatis screening rates were primarily influenced by risk factors rather than insurance coverage.

Michael Schatz, MD; Robert S. Zeiger, MD, PhD; David Mosen, PhD; and William M. Vollmer, PhD

Asthma-specific quality of life and a history of acute episodes can be used together to identify risks of subsequent acute exacerbations.

Susan M. Smith, MD; Shane Allwright, PhD; and Tom Oâ??Dowd, MD

Evidence to support the introduction of shared care services into clinical practice is limited, although methodologic shortcomings may account for this lack of evidence.

Paul C. Nagle, BSBA; Christopher A. Nicita, MBA; Leslie A. Gerdes, BA; and Cynthia J. Schmeichel, PhD

Research on characteristics of the biopharmaceutical pipeline and on changes since 2003 includes a description of new features and recommendations for health policy decision makers.

Vibeke Strand, MD; Jasvinder A. singh, MD, MPH